Viewing Study NCT01568866


Ignite Creation Date: 2025-12-24 @ 4:05 PM
Ignite Modification Date: 2026-01-29 @ 1:26 PM
Study NCT ID: NCT01568866
Status: COMPLETED
Last Update Posted: 2022-11-14
First Post: 2012-03-28
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
Sponsor: Amgen
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Multiple Myeloma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None multiple myeloma View
None relapsed multiple myeloma View